# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat adva...
AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymph...
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this se...
-Reuters
- Reuters
The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. FARXIGA was previously approved in the...
- Reuters
- Reuters
AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) has been accepted and granted Priority Re...